No Detail Found!

Anti-MOG Antibody Associated Disorders in Pakistan

Author(s)
Tahira Mohammad Department of Immunology, Shifa International Hospital Limited,Islamabad,Pakistan
Arsalan Ahmad Department of Neurology, Shifa International Hospital Limited,Islamabad,Pakistan
Tahir Aziz Ahmed Department of Immunology, Shifa International Hospital Limited,Islamabad,Pakistan
Abstract
To present clinicopathological features and treatment outcomes of patients who tested positive for anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in the catchment Pakistani population. Study Design: Observational study. Place and Duration of the Study: Department of Immunology and Neurology, Shifa International Hospital / Shifa Tameer-e-Millat University, Islamabad, Pakistan, from January 2018 to December 2022. Methodology: A review of patients referred for anti-MOG antibody testing was conducted. Indirect immuno uorescence was used to analyse all samples on EU 90 cells transfected with MOG genes. Patients who tested positive for anti-MOG antibodies were included in the study. Patients medical records and interviews were used to gather clinical data, as per the objective. Results: One hundred and fourteen patients out of 740 were tested positive for anti-MOG antibodies. A total of 59 patients were included for nal analysis, and 78 (68.4%) of the seropositive population were male, with a mean age of 24 years ± 15.8 years (range 4-59 years). The most frequent clinical presentation was visual impairment in 39/59 (66%) patients, followed by muscle weakness in 36/59 (61%) and headache in 30/59 (50%) patients. Treatment included intravenous methylprednisolone, oral prednisolone, plasma exchange, rituximab, intravenous immunoglobulins, azathioprine, mycophenolate mofetil, cyclophosphamide, and methotrexate. Conclusion: The present study showed a higher percentage of males tested positive for anti-MOG antibodies. MOG-associated disorders can a ect both children and adults. The most frequent clinical presentations of MOGAD in this study were visual impairment, followed by muscle weakness. The primary clinical phenotype identi ed was isolated transverse myelitis.
Publication Details
Page(s) 913-916
Published Journal: Journal of the College of Physicians and Surgeons Pakistan, Volume: 35, Issue: 07, Year: 2025

Request the full text from PASTIC

Keywords
Acute disseminated encephalomyelitis, Optic neuritis, Demyelinating disease, Autoimmune disorder, Myelin oligodendrocyte glycoprotein, Myelitis
References
Reindl M,Waters P .2019 .Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol, 10(2) : 89-102.
Takai Y,Misu T,Kaneko K,Chihara N,Narikawa K,Tsuchida S .2020 .Myelin oligodendrocyte glycoprotein antibodyassociated disease: An immunopathological study. Brain, 10(5) : 1431-46.
Li Y,Liu X,Wang J,Pan C,Z. C .2022 .Clinical features and imaging ndings of myelin oligodendrocyte glycoproteinIgG-associated disorder (MOGAD). Front Aging Neurosci, 850743 : 850743.
Ambrosius W,Michalak S,Kozubski W,Kalinowska A .2020 .Myelin oligodendrocyte glycoprotein antibody-associated disease: Current insights into the disease pathophysiology, diagnosis and management. Int J Mol Sci, 10(1) : 100.
de Mol CL,Wong Y,van Pelt ED,Wokke B,Siepman T,Neuteboom RF .2020 .The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler, 10(7) : 806-14.
Nakamura M,Ogawa R,Fujimori J,Uzawa A,Sato Y,Nagashima K .2023 .Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in a nationwide survey. Mult Scler, 10(4-5) : 530-9.
Leray E,Moreau T,Fromont A,Edan G .2015 .Epidemiology of multiple sclerosis. Rev Neurol, 10(1) : 3-13.
Banwell B,Bennett JL,Marignier R,Kim HJ,Brilot F,Flanagan EP .2023 .Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD panel proposed criteria. Lancet Neurol, 4422(22) : 00431-8.
Jarius S,Paul F,Aktas O,Asgari N,Dale RC,de Seze J .2018 .MOG encephalomyelitis: International recommendations on diagnosis and antibody testing. J Neuroin, 10(1) : 134.
Abrams BM,Waldman HJ .2008 .Electromyography and Evoked Potentials. Raj's Practical Management of Pain, : 297-321.
Chen C,Liu C,Fang L,Zou Y,Ruan H,Wang Y .2019 .Di erent magnetic resonance imaging features between MOG antibody- and AQP4 antibody-mediated disease: A Chinese cohort study. J Neurol Sci, 116430 : 116430.
Senanayake B,Jitprapaikulsan J,Aravinthan M,Wijesekera JC,Ranawaka UK,Ri sy MT .2019 .Seroprevalence and clinical phenotype of MOG-IgG-associated disorders in Sri Lanka. J Neurol Neurosurg Psychiatry, 10(12) : 1381-3.
Chen JJ,Flanagan EP,Bhatti MT,Jitprapaikulsan J,Dubey D,Chiriboga ASSL .2020 .Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology, 10(2) : e111-20.
Chaudhuri J,Biswas T,Ganguly G,Datta S,Pandit A,Biswas A,Ab A .2021 .-associated diseases: An Indian perspective. Acta Neurol Belg, 10(4) : 927-31.
Qayyum F,Sheikh S,Ahmad A,Ahmed T,Awan S .2019 .Anti-MOG antibody associated neurological disorders: A retrospective audit. J Neurol Sci, 10 : 72.
Jarius S,Ruprecht K,Kleiter I,Borisow N,Asgari N,Pitarokoili K .2016 .MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcomeJ. , 10(1) : 280.
Jarius S,Ruprecht K,Kleiter I,Borisow N,Asgari N,Pitarokoili K .2016 .MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 1: Frequency, syndrome speci city, in uence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroin, 10(1) : 279.
0

Citations

0

Downloads

58

Views